Your browser is no longer supported. Please, upgrade your browser.
Settings
KALA Kala Pharmaceuticals, Inc. daily Stock Chart
KALA [NASD]
Kala Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.30 Insider Own3.20% Shs Outstand35.78M Perf Week-4.98%
Market Cap204.66M Forward P/E- EPS next Y-2.35 Insider Trans476.69% Shs Float32.65M Perf Month-20.56%
Income-52.80M PEG- EPS next Q-0.52 Inst Own52.10% Short Float3.11% Perf Quarter-47.28%
Sales- P/S- EPS this Y-329.30% Inst Trans-9.02% Short Ratio2.90 Perf Half Y-57.97%
Book/sh2.23 P/B2.57 EPS next Y-6.80% ROA-52.70% Target Price24.20 Perf Year-68.04%
Cash/sh2.09 P/C2.73 EPS next 5Y- ROE-72.10% 52W Range5.49 - 20.17 Perf YTD-69.06%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-71.64% Beta-
Dividend %- Quick Ratio6.30 Sales past 5Y- Gross Margin- 52W Low4.19% ATR0.43
Employees37 Current Ratio6.30 Sales Q/Q- Oper. Margin- RSI (14)34.91 Volatility6.48% 6.80%
OptionableYes Debt/Eq0.36 EPS Q/Q-12.40% Profit Margin- Rel Volume0.36 Prev Close5.72
ShortableYes LT Debt/Eq0.30 EarningsNov 06 Payout- Avg Volume350.04K Price5.72
Recom1.40 SMA20-7.75% SMA50-23.38% SMA200-54.17% Volume126,329 Change0.00%
Nov-23-18 08:00AM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-08-18 07:56AM  Kala Pharma: 3Q Earnings Snapshot Associated Press
07:30AM  Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results Business Wire
Nov-07-18 04:05PM  Kala Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference Business Wire
Oct-25-18 08:00AM  Kala Pharmaceuticals Appoints Steven Zhang as Vice President of Medical Affairs Business Wire
Oct-24-18 08:55AM  New Research Coverage Highlights Vmware, Kala Pharmaceuticals, El Pollo Loco, Integer, AAC, and Vectren Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire -10.19%
Oct-19-18 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Oct-18-18 08:00AM  Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO Business Wire
Oct-16-18 08:00AM  Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease Business Wire +10.94%
Oct-11-18 04:01PM  Kala Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Oct-09-18 08:44AM  Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4% Zacks
Oct-03-18 11:58AM  Here's Why Kala Pharmaceuticals Fell as Much as 17.7% Today Motley Fool -15.52%
Oct-02-18 04:18PM  Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
04:18PM  Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million Business Wire
Sep-26-18 12:50PM  Is Kala Pharmaceuticals Incs (NASDAQ:KALA) Balance Sheet A Threat To Its Future? Simply Wall St. -8.09%
Sep-21-18 04:05PM  Kala Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-10-18 02:17PM  Six Biotechnology Names on My Watch List TheStreet.com
Aug-31-18 07:50AM  Research Report Identifies Holly Energy Partners, First Merchants, Enbridge Energy Management, Activision Blizzard, Coherus BioSciences, and Kala Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-29-18 04:01PM  Kala Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
09:38AM  Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA Zacks
Aug-23-18 03:28PM  U.S. FDA approves Kala Pharma's eye pain drug Reuters -7.20%
02:13PM  Kala stock declines 6% after FDA approves ocular surgery product MarketWatch
Aug-16-18 10:06AM  H.C. Wainwright Maintains Buy on Kala Pharmaceuticals (KALA) Ahead of Upcoming PDUFA Date SmarterAnalyst +6.50%
Aug-09-18 07:48AM  Kala Pharma: 2Q Earnings Snapshot Associated Press
07:00AM  Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results Business Wire
Aug-08-18 04:05PM  Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference Business Wire
Aug-02-18 09:16PM  Kala Pharmaceuticals (KALA), Durect (DRRX), and Amarin (AMRN) Reiterated with a Buy at H.C. Wainwright SmarterAnalyst
Jul-31-18 08:00AM  Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease Business Wire
Jul-27-18 07:55AM  Recent Analysis Shows Kala Pharmaceuticals, Integer, Carnival, Coty, Sykes Enterprises, and Agilent Technologies Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jul-23-18 07:28PM  According to H.C. Wainwright, This Biotech Stock Can Jump to $35 SmarterAnalyst
Jul-17-18 07:09AM  Kala Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-22-18 08:36AM  Options Traders Expect Huge Moves in Kala Pharmaceuticals (KALA) Stock Zacks
Jun-20-18 03:15PM  Wedbush Sees 240% Upside for Kala Pharmaceuticals (KALA) Stock; Heres Why SmarterAnalyst
Jun-19-18 04:01PM  Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan Business Wire
May-22-18 07:55AM  Market Trends Toward New Normal in Meredith, Weis Markets, Kala Pharmaceuticals, Fortress Transportation and Infrastructure Investors, Kraton, and Web.com Group Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-10-18 07:18AM  Kala Pharma: 1Q Earnings Snapshot Associated Press
07:00AM  Kala Pharmaceuticals Reports First Quarter 2018 Financial Results Business Wire
May-09-18 05:05PM  Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch Business Wire
May-08-18 08:00AM  Kala Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Apr-23-18 07:40AM  Wired News Capricors New Pre-Clinical Study Establishes that Repeated Doses of CAP-1002 Lead to Enhanced Exercise Capacity in a Disease Model of Duchenne Muscular Dystrophy ACCESSWIRE
Apr-09-18 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire +6.58%
08:00AM  Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS Business Wire
Apr-03-18 08:00AM  Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary Business Wire
Mar-28-18 08:10AM  Recent Analysis Shows Welltower, Integer, Jernigan Capital, ZTO EXPRESS INC, Kala Pharmaceuticals, and Covenant Transportation Group Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-26-18 04:48PM  Kala Pharmaceuticals, Inc. (KALA) Q4 2017 Earnings Conference Call Transcript Motley Fool -13.78%
07:23AM  Kala Pharma reports 4Q loss Associated Press
07:00AM  Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results Business Wire
Mar-19-18 08:00AM  Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call Business Wire
Mar-14-18 08:00AM  Kala Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference Business Wire
Mar-05-18 08:00AM  Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair Business Wire
Jan-26-18 04:48PM  Largest Insider Trades of the Week GuruFocus.com
Jan-25-18 08:10AM  New Research: Key Drivers of Growth for Comstock Resources, Varonis, Union Bankshares, Heidrick & Struggles International, Tejon Ranch, and Kala Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-05-18 04:32PM  Here's Why Kala Pharmaceuticals Got Crushed on Friday Motley Fool -29.28%
10:13AM  Kala shares decline 8% on late-stage trial results for dry eye therapy MarketWatch
09:46AM  Future of Kala Pharma's dry eye drug uncertain after mixed results Reuters
07:00AM  Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease Business Wire
06:50AM  Kala Pharmaceuticals Announces New Drug Application for INVELTYSTM (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration Business Wire
Nov-13-17 08:00AM  Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer Business Wire
Nov-07-17 07:30AM  Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update Business Wire
Oct-30-17 09:34AM  [$$] Private Equity Analyst's 2017 Women to Watch: Venture Capital The Wall Street Journal
Oct-25-17 08:00AM  Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYSTM (KPI-121 1%) Business Wire
Sep-05-17 08:00AM  Kala Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference Business Wire
Aug-14-17 01:57PM  Kala Pharma Has 2 Material Milestones Upcoming In Q4 Benzinga +9.31%
Jul-25-17 04:05PM  Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters Option Business Wire
Jul-23-17 10:36AM  IPOs This Week: Real Estate Unicorn Redfin Leads Weeks IPOs 24/7 Wall St.
Jul-20-17 11:36AM  Kala Pharmaceuticals Joins NASDAQ, the Biotech IPOs Keep Coming TheStreet.com
10:49AM  [$$] Kala Pharmaceuticals Prices IPO at Midpoint of Range The Wall Street Journal
08:06AM  Kala Pharmaceuticals prices IPO at $15 a share MarketWatch
08:00AM  Kala Pharmaceuticals Announces Pricing of Initial Public Offering Business Wire
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grunberg GregoryDirectorOct 05Buy8.25606,0604,999,9952,877,006Oct 09 04:46 PM
Shah Rajeev M.DirectorOct 03Buy8.252,424,24219,999,9974,537,478Oct 05 04:34 PM
RA CAPITAL MANAGEMENT, LLCDirectorOct 03Buy8.252,424,24219,999,9974,537,478Oct 05 04:33 PM
Chen HongmingChief Scientific OfficerFeb 28Option Exercise2.269,76922,12355,849Mar 02 05:19 PM
ORBIMED ADVISORS LLC10% OwnerFeb 08Buy12.9325,000323,2503,447,840Feb 12 04:35 PM
ORBIMED ADVISORS LLC10% OwnerFeb 02Buy14.7337,840557,3833,422,840Feb 06 05:05 PM
ORBIMED ADVISORS LLC10% OwnerFeb 01Buy14.9922,840342,3723,385,000Feb 02 05:45 PM
ORBIMED ADVISORS LLC10% OwnerJan 31Buy15.00339,4005,091,0003,362,160Feb 02 05:45 PM
ORBIMED ADVISORS LLC10% OwnerJan 29Buy14.9950,000749,5003,022,760Jan 30 03:34 PM
ORBIMED ADVISORS LLC10% OwnerJan 26Buy14.9322,760339,8072,972,760Jan 30 03:34 PM
ORBIMED ADVISORS LLC10% OwnerJan 24Buy14.9164,637963,7382,950,000Jan 24 08:59 PM
ORBIMED ADVISORS LLC10% OwnerJan 23Buy14.994,36365,4012,885,363Jan 24 08:59 PM
ORBIMED ADVISORS LLC10% OwnerJan 22Buy14.9875,0001,123,5002,881,000Jan 24 08:59 PM
ORBIMED ADVISORS LLC10% OwnerJan 19Buy14.9574,9311,120,2182,806,000Jan 24 08:59 PM
ORBIMED ADVISORS LLC10% OwnerJan 12Buy14.5038,354556,1332,731,069Jan 24 08:59 PM
ORBIMED ADVISORS LLC10% OwnerJan 12Buy15.4028,446438,0682,692,715Jan 12 05:29 PM
ORBIMED ADVISORS LLC10% OwnerJan 11Buy13.6541,700569,2052,664,269Jan 12 05:29 PM
ORBIMED ADVISORS LLC10% OwnerJan 10Buy12.83170,3382,185,4372,622,569Jan 12 05:29 PM